Design and Rationale for the Use of Magnetic Resonance Imaging Biomarkers to Predict Diabetes After Acute Pancreatitis in the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium.

Autor:	Tirkes T; From the Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN., Chinchilli VM; Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA., Bagci U, Parker JG; From the Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN., Zhao X; From the Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN., Dasyam AK; Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, PA., Feranec N; Department of Radiology, AdventHealth, Orlando, FL., Grajo JR; Department of Radiology, College of Medicine, University of Florida, Gainesville, FL., Shah ZK; Department of Radiology, Ohio State University Wexner Medical Center, Columbus, OH., Poullos PD, Spilseth B; Department of Radiology, University of Minnesota Medical School, Minneapolis, MN., Zaheer A; Department of Radiology, Johns Hopkins Medicine, Baltimore, MD., Xie KL; Department of Radiology, University of Illinois at Chicago, Chicago, IL., Wachsman AM; Department of Radiology, Cedars Sinai Medical Center, Los Angeles, CA., Campbell-Thompson M; Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL., Conwell DL; Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH., Fogel EL; Lehman, Bucksot and Sherman Section of Pancreatobiliary Endoscopy, Indiana University School of Medicine, Indianapolis, IN., Forsmark CE; Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL., Hart PA; Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH., Pandol SJ; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles., Park WG; Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Stanford, CA., Pratley RE; AdventHealth Translational Research Institute, Orlando, FL., Yazici C; Division of Gastroenterology and Hepatology, Department of Medicine, University of Illinois at Chicago, Chicago, IL., Laughlin MR; Divisions of Diabetes, Endocrinology, and Metabolic Diseases., Andersen DK; Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD., Serrano J; Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD., Bellin MD, Yadav D; Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Jazyk:	angličtina
Zdroj:	Pancreas [Pancreas] 2022 Jul 01; Vol. 51 (6), pp. 586-592.
DOI:	10.1097/MPA.0000000000002080
Abstrakt:	Abstract: This core component of the Diabetes RElated to Acute pancreatitis and its Mechanisms (DREAM) study will examine the hypothesis that advanced magnetic resonance imaging (MRI) techniques can reflect underlying pathophysiologic changes and provide imaging biomarkers that predict diabetes mellitus (DM) after acute pancreatitis (AP). A subset of participants in the DREAM study will enroll and undergo serial MRI examinations using a specific research protocol. The aim of the study is to differentiate at-risk individuals from those who remain euglycemic by identifying parenchymal features after AP. Performing longitudinal MRI will enable us to observe and understand the natural history of post-AP DM. We will compare MRI parameters obtained by interrogating tissue properties in euglycemic, prediabetic, and incident diabetes subjects and correlate them with metabolic, genetic, and immunological phenotypes. Differentiating imaging parameters will be combined to develop a quantitative composite risk score. This composite risk score will potentially have the ability to monitor the risk of DM in clinical practice or trials. We will use artificial intelligence, specifically deep learning, algorithms to optimize the predictive ability of MRI. In addition to the research MRI, the DREAM study will also correlate clinical computed tomography and MRI scans with DM development. Competing Interests: Besides the funding support from NIH listed about, C.E.F. receives consultant fee or honorarium from Nestle HealthCare Nutrition, Inc, Parexel International Corp, and Medialis, Ltd. M.D.B. is an advisory board member of Insulet and receives research support from Dexcom and Viacyte. S.J.P. owns stock options of Avenzoar Pharmaceuticals, Phyteau, and Lucid Sciences. W.G.P. is a consultant for AbbVie. B.S. is a consultant for Francis Medical and Botimage. T.T. receives royalties from Springer Nature. J.R.G. receives royalties from Elsevier, Inc. D.K.A. receives royalties from McGraw-Hill. R.E.P. is consultant for Bayer AG, Corcept Therapeutics Incorporated, Dexcom, Gasherbrum Bio, Inc, Hanmi Pharmaceutical Co, Hengrui (USA) Ltd, Merck, Novo Nordisk, Pfizer, Rivus Pharmaceuticals, Inc, Sanofi, Scohia Pharma Inc, and Sun Pharmaceutical Industries and receives speaker fees from Novo Nordisk. The other authors declare no conflict of interest. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu